Literature DB >> 22136837

Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.

Dana T Yip1, Maria Hassan, Kalliopi Pazaitou-Panayiotou, Daniel T Ruan, Atul A Gawande, Randall D Gaz, Francis D Moore, Richard A Hodin, Antonia E Stephen, Peter M Sadow, Gilbert H Daniels, Gregory W Randolph, Sareh Parangi, Carrie C Lubitz.   

Abstract

BACKGROUND: The optimal initial operative management of medullary thyroid cancer (MTC) and the use of biomarkers to guide the extent of operation remain controversial. We hypothesized that preoperative serum levels of calcitonin and carcinoembryonic antigen (CEA) correlate with extent of disease and postoperative levels reflect the extent of operation performed.
METHODS: We assessed retrospectively clinical and pathologic factors among patients with MTC undergoing at least total thyroidectomy; these factors were correlated with biomarkers using regression analyses.
RESULTS: Data were obtained from 104 patients, 28% with hereditary MTC. Preoperative calcitonin correlated with tumor size (P < .001) and postoperative serum calcitonin levels (P = .01) after multivariable adjustment for lymph node positivity, extent of operation, and hereditary MTC. No patient with a preoperative calcitonin level of <53 pg/mL (n = 20) had lymph node metastases. TNM stage (P = .001) and preoperative calcitonin levels (P = .04), but not extent of operation, independently correlated with the failure to normalize postoperative calcitonin. Postoperative CEA correlated with positive margins (adjusted P = 04). Neither preoperative nor postoperative CEA was correlated with lymph node positivity or extent of surgery.
CONCLUSION: Preoperative serum calcitonin and TMN stage, but not extent of operation, were independent predictors of postoperative normalization of serum calcitonin levels. Future studies should evaluate preoperative serum calcitonin levels as a determinate of the extent of initial operation.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136837      PMCID: PMC3880195          DOI: 10.1016/j.surg.2011.09.043

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  27 in total

Review 1.  [Type 2 endocrine neoplasms. Clinical aspects].

Authors:  E Modigliani
Journal:  Presse Med       Date:  1998-04-04       Impact factor: 1.228

2.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.

Authors:  E Modigliani; R Cohen; J M Campos; B Conte-Devolx; B Maes; A Boneu; M Schlumberger; J C Bigorgne; P Dumontier; L Leclerc; B Corcuff; I Guilhem
Journal:  Clin Endocrinol (Oxf)       Date:  1998-03       Impact factor: 3.478

3.  Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas.

Authors:  T Weber; T Schilling; K Frank-Raue; M Colombo-Benkmann; U Hinz; R Ziegler; E Klar
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

4.  Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.

Authors:  F Pacini; M Fontanelli; L Fugazzola; R Elisei; C Romei; G Di Coscio; P Miccoli; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1994-04       Impact factor: 5.958

5.  Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection.

Authors:  J F Moley; M K DeBenedetti
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

6.  Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).

Authors:  R Cohen; J M Campos; C Salaün; H M Heshmati; J L Kraimps; C Proye; E Sarfati; J F Henry; P Niccoli-Sire; E Modigliani
Journal:  J Clin Endocrinol Metab       Date:  2000-02       Impact factor: 5.958

7.  Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.

Authors:  Cristina Romei; Stefano Mariotti; Laura Fugazzola; Augusto Taccaliti; Furio Pacini; Giuseppe Opocher; Caterina Mian; Maurizio Castellano; Ettore degli Uberti; Isabella Ceccherini; Nadia Cremonini; Ettore Seregni; Fabio Orlandi; Piero Ferolla; Efisio Puxeddu; Francesco Giorgino; Annamaria Colao; Paola Loli; Fabio Bondi; Barbara Cosci; Valeria Bottici; Antonello Cappai; Giovanni Pinna; Luca Persani; Uberta Verga; Verga Uberta; Marco Boscaro; Maria Grazia Castagna; Carlo Cappelli; Maria Chiara Zatelli; Antongiulio Faggiano; Giuseppe Francia; Maria Luisa Brandi; Alberto Falchetti; Aldo Pinchera; Rossella Elisei
Journal:  Eur J Endocrinol       Date:  2010-06-01       Impact factor: 6.664

8.  Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer.

Authors:  Maria A Kouvaraki; Suzanne E Shapiro; Bruno D Fornage; Beth S Edeiken-Monro; Steven I Sherman; Rena Vassilopoulou-Sellin; Jeffrey E Lee; Douglas B Evans
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

9.  Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.

Authors:  Claudia Scollo; Eric Baudin; Jean-Paul Travagli; Bernard Caillou; Nicolas Bellon; Sophie Leboulleux; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

10.  Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.

Authors:  Rossella Elisei; Valeria Bottici; Fabiana Luchetti; Giancarlo Di Coscio; Cristina Romei; Lucia Grasso; Paolo Miccoli; Pietro Iacconi; Fulvio Basolo; Aldo Pinchera; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

View more
  12 in total

Review 1.  Calcitonin as a biomarker of C cell disease: recent achievements and current challenges.

Authors:  Giuseppe Costante; Domenico Meringolo
Journal:  Endocrine       Date:  2020-01-10       Impact factor: 3.633

2.  Concurrent Medullary, Papillary, and Follicular Thyroid Carcinomas and Simultaneous Cushing's Syndrome.

Authors:  Haggi Mazeh; Amir Orlev; Ido Mizrahi; David J Gross; Herbert R Freund
Journal:  Eur Thyroid J       Date:  2014-11-22

3.  Large sporadic thyroid medullary carcinomas: predictive factors for lymph node involvement.

Authors:  Sébastien Aubert; Amandine Berdelou; Viviane Gnemmi; Hélène Behal; Robert Caiazzo; Michèle D'herbomez; Pascal Pigny; Jean Louis Wemeau; Bruno Carnaille; Florence Renaud; Brigitte Bouchindhomme; Emmanuelle Leteurtre; Michael Perrais; François Pattou; Christine Do Cao
Journal:  Virchows Arch       Date:  2018-02-01       Impact factor: 4.064

4.  Lymph Node Metastases of Medullary Thyroid Cancer: Role of Calcitonin in the Washout Fluid of Fine-Needle Aspiration.

Authors:  Bernardo Marques; Nuno Cunha; Raquel G Martins; Ana Rita Elvas; Joana Couto; Jacinta Santos; Teresa Martins; Ana Paula Moniz; Olga Ilhéu; Frederico Valido; Fernando Rodrigues
Journal:  Int J Endocrinol       Date:  2020-04-04       Impact factor: 3.257

5.  Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma.

Authors:  Hyunju Park; So Young Park; Jun Park; Jun Ho Choe; Man Ki Chung; Sook-Young Woo; Joon Young Choi; Sun Wook Kim; Jae Hoon Chung; Tae Hyuk Kim
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-05       Impact factor: 5.555

6.  Extension of Prophylactic Surgery in Medullary Thyroid Carcinoma. Differences Between Sporadic and Hereditary Tumours According to Calcitonin Levels and Lymph Node Involvement.

Authors:  L D Juez; E Mercader; I Amunategui; B Febrero; J M Rodríguez; J Gómez-Ramírez
Journal:  World J Surg       Date:  2022-01-28       Impact factor: 3.352

Review 7.  A Review of the Significance in Measuring Preoperative and Postoperative Carcinoembryonic Antigen (CEA) Values in Patients with Medullary Thyroid Carcinoma (MTC).

Authors:  Ioannis Passos; Elisavet Stefanidou; Soultana Meditskou-Eythymiadou; Maria Mironidou-Tzouveleki; Vasiliki Manaki; Vasiliki Magra; Styliani Laskou; Stylianos Mantalovas; Stelian Pantea; Isaak Kesisoglou; Konstantinos Sapalidis
Journal:  Medicina (Kaunas)       Date:  2021-06-11       Impact factor: 2.430

8.  Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.

Authors:  Sena Turkdogan; Véronique-Isabelle Forest; Michael P Hier; Michael Tamilia; Anca Florea; Richard J Payne
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-09-17

9.  Prognostic value of numbers of metastatic lymph node in medullary thyroid carcinoma: A population-based study using the SEER 18 database.

Authors:  Kexin Meng; Hua Luo; Hailong Chen; Haiwei Guo; Wenjie Xia
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

10.  Medullary Thyroid Carcinoma With Elevated Serum CEA and Normal Serum Calcitonin After Surgery: A Case Report and Literature Review.

Authors:  Li Chen; Ke Zhao; Fuxin Li; Xianghui He
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.